Celgene (CELG) Tops Q2 EPS by 4c, Raise FY EPS Guiadnce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celgene Reports Second Quarter 2017 Operating and Financial Results
July 27, 2017 7:30 AM EDT- Strong Q2 performance; Updated 2017 EPS guidance
- Positive ozanimod phase III data in relapsing multiple sclerosis (RMS) advances neuroscience franchise opportunities
- Completed enrollment in five phase III trials during Q2, with data expected in 2018; Multiple phase III data readouts expected in H2:17
- BGB-A317 (PD-1 inhibitor) transaction accelerates immuno-oncology strategy in solid tumors
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $3,256 million for the second quarter of 2017, a 19 percent increase from... More
